NYSEAMERICAN:PLX Protalix BioTherapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.07 -0.04 (-3.60%) (As of 06/28/2022 12:00 AM ET) Add Compare Share Today's Range$1.07▼$1.1250-Day Range N/A52-Week Range$0.70▼$2.00Volume106,024 shsAverage Volume2.10 million shsMarket Capitalization$50.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PLX Stock Forecast (MarketRank)Overall MarketRank™1.31 out of 5 starsAnalyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Protalix BioTherapeutics. Previous Next 4.3 Community Rank Outperform VotesProtalix BioTherapeutics has received 226 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProtalix BioTherapeutics has received 123 “underperform” votes. (Add your “underperform” vote.)Community SentimentProtalix BioTherapeutics has received 64.76% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Protalix BioTherapeutics and other stocks. Vote “Outperform” if you believe PLX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProtalix BioTherapeutics does not currently pay a dividend.Dividend GrowthProtalix BioTherapeutics does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protalix BioTherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $102,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.27% of the stock of Protalix BioTherapeutics is held by insiders.Percentage Held by InstitutionsOnly 15.67% of the stock of Protalix BioTherapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Protalix BioTherapeutics are expected to grow in the coming year, from ($0.59) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protalix BioTherapeutics is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protalix BioTherapeutics is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Protalix BioTherapeutics (NYSEAMERICAN:PLX)Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.Read More PLX Stock News HeadlinesMay 26, 2022 | finance.yahoo.comProtalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry DiseaseMay 17, 2022 | finance.yahoo.comPLX: First Quarter Financial and Operational ReviewMay 16, 2022 | seekingalpha.comProtalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q1 2022 Results - Earnings Call TranscriptMay 16, 2022 | nasdaq.comProtalix BioTherapeutics Inc. Q1 Loss decreases, but misses estimatesMay 13, 2022 | seekingalpha.comPLx Pharma (PLXP) CEO, Natasha Giordano on Q1 2022 Results - Earnings Call TranscriptMay 9, 2022 | finance.yahoo.comProtalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022April 13, 2022 | investing.comAfter-Hours Stock Movers 04/13: (AIRG) (VERU) (PLX) Higher; (CMBM) (RENT) Lower (more...)April 7, 2022 | finance.yahoo.com10 Penny Stocks to Buy in AprilApril 5, 2022 | finance.yahoo.comPLX: Topline Results from BALANCEApril 4, 2022 | marketwatch.comProtalix BioTherapeutics Shares Jump 73% After Positive Trial Results for PRX-102April 4, 2022 | benzinga.comWhy Protalix BioTherapeutics Stock Is SoaringApril 4, 2022 | markets.businessinsider.comProtalix BioTherapeutics Reports Positive Topline Results From BALANCE Phase III TrialApril 4, 2022 | finance.yahoo.comProtalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry DiseaseSee More Headlines Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PLX Previous SymbolNYSEMKT:PLX CUSIPN/A CIK1006281 Webwww.protalix.com Phone(201) 696-9345Fax972-4988-9489Employees202Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today6/29/2022Next Earnings (Estimated)8/15/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($0.450010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6.52 million Net Margins-41.62% Pretax Margin-41.62% Return on EquityN/A Return on Assets-22.65% Debt Debt-to-Equity Ratio130.59 Current Ratio1.67 Quick Ratio1.32 Sales & Book Value Annual Sales$62.90 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($0.81) per share Price / Book-1.32Miscellaneous Outstanding Shares47,063,000Free Float44,067,000Market Cap$50.36 million OptionableOptionable Beta2.19 Protalix BioTherapeutics Frequently Asked Questions Are investors shorting Protalix BioTherapeutics? Protalix BioTherapeutics saw a decline in short interest in the month of May. As of May 31st, there was short interest totaling 2,740,000 shares, a decline of 27.7% from the May 15th total of 3,790,000 shares. Based on an average daily trading volume, of 3,700,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 7.2% of the company's shares are short sold. View Protalix BioTherapeutics' Short Interest. When is Protalix BioTherapeutics' next earnings date? Protalix BioTherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for Protalix BioTherapeutics. How were Protalix BioTherapeutics' earnings last quarter? Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) issued its quarterly earnings results on Monday, May, 16th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $16.09 million for the quarter. View Protalix BioTherapeutics' earnings history. When did Protalix BioTherapeutics' stock split? How did Protalix BioTherapeutics' stock split work? Protalix BioTherapeutics's stock reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of Protalix BioTherapeutics stock prior to the reverse split would have 10 shares after the split. Who are Protalix BioTherapeutics' key executives? Protalix BioTherapeutics' management team includes the following people: Mr. Dror Bashan, Pres, CEO & Director (Age 55, Pay $490.1k)Mr. Eyal Rubin M.B.A., Sr. VP, CFO, Treasurer & Corp. Sec. (Age 46, Pay $430.56k)Dr. Einat Brill-Almon Ph.D., Sr. VP & Chief Devel. Officer (Age 62, Pay $430.98k)Mr. Yaron Naos, Sr. VP of Operations (Age 58)Ms. Dafna Shelly M.Sc., MBA, VP of HR Who are some of Protalix BioTherapeutics' key competitors? Some companies that are related to Protalix BioTherapeutics include CEL-SCI (CVM), CEL-SCI (CVM), Acumen Pharmaceuticals (ABOS), Scholar Rock (SRRK), Dynamics Special Purpose (DYNS), Gritstone bio (GRTS), Genfit (GNFT), Graphite Bio (GRPH), Ikena Oncology (IKNA), Jounce Therapeutics (JNCE), Taysha Gene Therapies (TSHA), INmune Bio (INMB), Fennec Pharmaceuticals (FENC), ARYA Sciences Acquisition Corp IV (ARYD) and Poseida Therapeutics (PSTX). View all of PLX's competitors. What other stocks do shareholders of Protalix BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Novavax (NVAX), BioLineRx (BLRX), VBI Vaccines (VBIV), Sangamo Therapeutics (SGMO), Verastem (VSTM), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and CRISPR Therapeutics (CRSP). What is Protalix BioTherapeutics' stock symbol? Protalix BioTherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX." Who are Protalix BioTherapeutics' major shareholders? Protalix BioTherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Meitav Dash Investments Ltd. (0.53%), Spire Wealth Management (0.32%), Jane Street Group LLC (0.31%), Group One Trading L.P. (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Company insiders that own Protalix BioTherapeutics stock include Aharon Schwartz, Dror Bashan and Pharma Technologies Ltd Dexcel. View institutional ownership trends for Protalix BioTherapeutics. Which institutional investors are selling Protalix BioTherapeutics stock? PLX stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., and Simplex Trading LLC. View insider buying and selling activity for Protalix BioTherapeutics or view top insider-selling stocks. Which institutional investors are buying Protalix BioTherapeutics stock? PLX stock was purchased by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., Jane Street Group LLC, and Spire Wealth Management. View insider buying and selling activity for Protalix BioTherapeutics or or view top insider-buying stocks. How do I buy shares of Protalix BioTherapeutics? Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Protalix BioTherapeutics' stock price today? One share of PLX stock can currently be purchased for approximately $1.07. How much money does Protalix BioTherapeutics make? Protalix BioTherapeutics (NYSEAMERICAN:PLX) has a market capitalization of $50.36 million and generates $62.90 million in revenue each year. The company earns $-6.52 million in net income (profit) each year or ($0.450010) on an earnings per share basis. How many employees does Protalix BioTherapeutics have? Protalix BioTherapeutics employs 202 workers across the globe. How can I contact Protalix BioTherapeutics? Protalix BioTherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The official website for Protalix BioTherapeutics is www.protalix.com. The company can be reached via phone at (201) 696-9345, via email at [email protected], or via fax at 972-4988-9489. This page (NYSEAMERICAN:PLX) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
